– USA, MA / CHINA, Beijing – CANbridge Pharmaceuticals, Inc. (HKG: 1228), a China-based global biopharmaceutical company committed to the research, development, and commercialization of transformative rare disease and rare oncology therapies, today announced the appointment of Dr. Lan Hu (Ph.D.) to its Board as an independent, non-executive Director, effective as of February 16, 2022.
“We are delighted to welcome Dr. Hu to the CANbridge Board, where her wealth of leadership and insight in healthcare delivery, as well as her board positions in the medical and healthcare industries, will provide invaluable experience and perspective as we implement our strategy of integrated product development and commercialization operations on a deep level,” said Founder, Chairman, and CEO, Dr. James Xue.
Dr. Lan Hu will also join the remuneration committee.
About Dr. Lan Hu
Dr. Hu has a rich background in healthcare investment, operations, and administrative management and is a seasoned entrepreneur, having founded Beijing Amcare Women’s & Children’s Hospital Co. in 2004, where she also served as Director, Chairman of the Board and GM.
Currently, she is the Chairman of the Board and General Manager of Beijing Amcare Medical Management Co., Ltd.; the Chairman of the Board of Beijing Meizhong Airui Tumor Hospital Co., Ltd.; the independent Director of Beijing Yida Shidai Technology Development Co., Ltd. and the Executive Director and General Manager of Beijing Xuanhe Yazhi Management Consulting Co., Ltd. Dr. Hu is a member of 12th and 13th Beijing Municipal Committee of the Chinese People’s Political Consultative Conference, a position she has held since 2013. From 2002-2004, she was an Investment Manager at JP Morgan Chase Bank.
“I believe that I am joining the CANbridge Board at just the right time, as the company moves forward aggressively in developing and commercializing therapeutics that could make a difference to patients,” said Dr. Lan Hu. “I look forward to contributing to the next level of success at this dynamic company.”
Dr. Hu has a Ph.D. in medical sciences from Northeast Ohio Medical University, in Rootstown, Ohio, and a Master’s Degree in Business Administration from
The University of Michigan, in Ann Arbor, Michigan. She has a Bachelor’s Degree in medicine from Peking University, in Beijing, China.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a China-based global biopharmaceutical company committed to the research, development, and commercialization of transformative therapies for rare diseases and rare oncology.
CANbridge has a comprehensive and differentiated pipeline of 13 drug assets with significant market potential, targeting some of the most prevalent rare diseases and rare oncology. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme.
CANbridge strategically combines global collaborations and internal research to build and diversify its drug portfolio and invest in next-generation gene therapy technologies for rare disease treatments. CANbridge global partners include, but are not limited to, Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the University of Massachusetts Medical School, and LogicBio.
For more information: https://www.canbridgepharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.